“MIATA”——关于T细胞检测的最低限度信息
"MIATA"-minimal information about T cell assays.
作者信息
Janetzki Sylvia, Britten Cedrik M, Kalos Michael, Levitsky Hyam I, Maecker Holden T, Melief Cornelius J M, Old Lloyd J, Romero Pedro, Hoos Axel, Davis Mark M
出版信息
Immunity. 2009 Oct 16;31(4):527-8. doi: 10.1016/j.immuni.2009.09.007.
Abstract
Immunotherapy, especially therapeutic vaccination, has a great deal of potential in the treatment of cancer and certain infectious diseases such as HIV (Allison et al., 2006; Fauci et al., 2008; Feldmann and Steinman, 2005). Numerous vaccine candidates have been tested in patients with a variety of tumor types and chronic viral diseases. Often, the best way to assess the clinical potential of these vaccines is to monitor the induced T cell response, and yet there are currently no standards for reporting these results. This letter is an effort to address this problem.
摘要
免疫疗法，尤其是治疗性疫苗接种，在癌症及某些传染病（如HIV）的治疗中具有巨大潜力（Allison等人，2006年；Fauci等人，2008年；Feldmann和Steinman，2005年）。众多候选疫苗已在患有各种肿瘤类型和慢性病毒性疾病的患者中进行了测试。通常，评估这些疫苗临床潜力的最佳方法是监测诱导的T细胞反应，然而目前尚无报告这些结果的标准。本信函旨在解决这一问题。
相似文献
1
"MIATA"-minimal information about T cell assays.
Immunity. 2009 Oct 16;31(4):527-8. doi: 10.1016/j.immuni.2009.09.007.
2
The role of the reporting framework MIATA within current efforts to advance immune monitoring.
J Immunol Methods. 2014 Jul;409:6-8. doi: 10.1016/j.jim.2014.05.003. Epub 2014 May 9.
3
Immunization delivered by lentiviral vectors for cancer and infectious diseases.
Immunol Rev. 2011 Jan;239(1):45-61. doi: 10.1111/j.1600-065X.2010.00967.x.
4
[The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].
An Sist Sanit Navar. 2006 Jan-Apr;29(1):77-96. doi: 10.4321/s1137-66272006000100007.
5
Immunologic monitoring of cellular immune responses in cancer vaccine therapy.
J Biomed Biotechnol. 2011;2011:370374. doi: 10.1155/2011/370374. Epub 2011 Jun 7.
6
CoVal fusions: a therapeutic vaccine platform using heat shock proteins to treat chronic viral infection and cancer.
Dev Biol (Basel). 2004;116:193-200; discussion 229-36.
7
Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade.
Nat Commun. 2019 Jun 19;10(1):2688. doi: 10.1038/s41467-019-10594-2.
8
T-cell-inducing vaccines - what's the future.
Immunology. 2012 Jan;135(1):19-26. doi: 10.1111/j.1365-2567.2011.03517.x.
9
Developments in virus-like particle-based vaccines for infectious diseases and cancer.
Expert Rev Vaccines. 2011 Nov;10(11):1569-83. doi: 10.1586/erv.11.135.
10
Therapeutic vaccines for human papillomaviruses.
Intervirology. 2001;44(2-3):167-75. doi: 10.1159/000050044.
引用本文的文献
1
Adjuvant dendritic cell-based immunotherapy in melanoma: insights into immune cell dynamics and clinical evidence from a phase II trial.
J Transl Med. 2025 Apr 18;23(1):455. doi: 10.1186/s12967-025-06403-8.
2
A Winning New Combination? Toward Clinical Application in Oncology.
Cancer Control. 2023 Jan-Dec;30:10732748231175240. doi: 10.1177/10732748231175240.
3
Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials.
Front Immunol. 2023 Mar 7;14:1090533. doi: 10.3389/fimmu.2023.1090533. eCollection 2023.
4
A Highly Sensitive Flow Cytometric Approach to Detect Rare Antigen-Specific T Cells: Development and Comparison to Standard Monitoring Tools.
Cancers (Basel). 2023 Jan 17;15(3):574. doi: 10.3390/cancers15030574.
5
Modeling community standards for metadata as templates makes data FAIR.
Sci Data. 2022 Nov 12;9(1):696. doi: 10.1038/s41597-022-01815-3.
6
T cell immunity is key to the pandemic endgame: How to measure and monitor it.
Curr Res Immunol. 2022;3:215-221. doi: 10.1016/j.crimmu.2022.08.004. Epub 2022 Sep 1.
7
Comparison of Rapid Cytokine Immunoassays for Functional Immune Phenotyping.
Front Immunol. 2022 Jul 4;13:940030. doi: 10.3389/fimmu.2022.940030. eCollection 2022.
8
Minimal Information about MHC Multimers (MIAMM).
J Immunol. 2022 Feb 1;208(3):531-537. doi: 10.4049/jimmunol.2100961.
9
Unsupervised Analysis of Flow Cytometry Data in a Clinical Setting Captures Cell Diversity and Allows Population Discovery.
Front Immunol. 2021 Apr 30;12:633910. doi: 10.3389/fimmu.2021.633910. eCollection 2021.
10
Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients.
PLoS One. 2021 Feb 5;16(2):e0246191. doi: 10.1371/journal.pone.0246191. eCollection 2021.
本文引用的文献
1
A chromatic explosion: the development and future of multiparameter flow cytometry.
Immunology. 2008 Dec;125(4):441-9. doi: 10.1111/j.1365-2567.2008.02989.x.
2
A prescription for human immunology.
Immunity. 2008 Dec 19;29(6):835-8. doi: 10.1016/j.immuni.2008.12.003.
3
Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project.
Nat Biotechnol. 2008 Aug;26(8):889-96. doi: 10.1038/nbt.1411.
4
HIV vaccine research: the way forward.
Science. 2008 Jul 25;321(5888):530-2. doi: 10.1126/science.1161000.
5
Toward the harmonization of immune monitoring in clinical trials: quo vadis?
Cancer Immunol Immunother. 2008 Mar;57(3):285-8. doi: 10.1007/s00262-007-0379-z. Epub 2007 Aug 25.
6
A clinical development paradigm for cancer vaccines and related biologics.
J Immunother. 2007 Jan;30(1):1-15. doi: 10.1097/01.cji.0000211341.88835.ae.
7
Design of effective immunotherapy for human autoimmunity.
Nature. 2005 Jun 2;435(7042):612-9. doi: 10.1038/nature03727.
8
One-stop shop for microarray data.
Nature. 2000 Feb 17;403(6771):699-700. doi: 10.1038/35001676.
Zotero 插件